Physician profile
Michael J Maresca
NPI 1194893727
$1,382.43
in general payments reported to CMS, 2019-2025
22 companies · $444 in 2025
The $444 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2020: $204 · 2021: $44.92 · 2022: $297 · 2023: $108 · 2024: $66.52 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $416 · Education: $202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $416.40 |
| Education | $202.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $162.45 | 2020-2023 | Erleada |
| Emd Serono, INC. | $145.93 | 2019-2025 | |
| Pfizer INC. | $123.44 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $119.66 | 2022 | |
| Incyte Corporation | $112.55 | 2019-2025 | Jakafi |
| Aveo Pharmaceuticals, INC. | $99.00 | 2025 | |
| Amgen INC. | $74.13 | 2019-2023 | Xgeva, Nplate |
| Apellis Pharmaceuticals, INC. | $65.90 | 2022-2023 | Empaveli |
| Lilly USA, LLC | $64.21 | 2022-2024 | Retevmo, Jaypirca, Verzenio |
| Ipsen Biopharmaceuticals, INC | $61.94 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $47.82 | 2020-2021 | |
| Eisai INC. | $46.50 | 2022-2025 | |
| Genentech USA, INC. | $37.50 | 2019-2025 | Polivy |
| Seagen INC. | $33.08 | 2019 | |
| Astellas Pharma US INC | $32.48 | 2019-2025 | Padcev |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Menarini Silicon Biosystems, INC. | $29.81 | 2025 | |
| Daiichi Sankyo INC. | $29.02 | 2025 | Enhertu |
| Celgene Corporation | $27.68 | 2025 | Reblozyl |
| Merck Sharp & Dohme LLC | $23.20 | 2024 | Keytruda |
| Astrazeneca Pharmaceuticals Lp | $18.65 | 2022 | |
| Alexion Pharmaceuticals, INC. | $15.51 | 2019 | |
| Acrotech Biopharma INC. | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Maresca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.